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Abstract
Estrogens produce biological effects by interacting with two estrogen receptors, ERa and ERb. Drugs that selectively target
ERa or ERb might be safer for conditions that have been traditionally treated with non-selective estrogens. Several synthetic
and natural ERb-selective compounds have been identified. One class of ERb-selective agonists is represented by ERB-041
(WAY-202041) which binds to ERb much greater than ERa. A second class of ERb-selective agonists derived from plants
include MF101, nyasol and liquiritigenin that bind similarly to both ERs, but only activate transcription with ERb.
Diarylpropionitrile represents a third class of ERb-selective compounds because its selectivity is due to a combination of
greater binding to ERb and transcriptional activity. However, it is unclear if these three classes of ERb-selective compounds
produce similar biological activities. The goals of these studies were to determine the relative ERb selectivity and pattern of
gene expression of these three classes of ERb-selective compounds compared to estradiol (E2), which is a non-selective ER
agonist. U2OS cells stably transfected with ERa or ERb were treated with E2 or the ERb-selective compounds for 6 h.
Microarray data demonstrated that ERB-041, MF101 and liquiritigenin were the most ERb-selective agonists compared to
estradiol, followed by nyasol and then diarylpropionitrile. FRET analysis showed that all compounds induced a similar
conformation of ERb, which is consistent with the finding that most genes regulated by the ERb-selective compounds were
similar to each other and E2. However, there were some classes of genes differentially regulated by the ERb agonists and E2.
Two ERb-selective compounds, MF101 and liquiritigenin had cell type-specific effects as they regulated different genes in
HeLa, Caco-2 and Ishikawa cell lines expressing ERb. Our gene profiling studies demonstrate that while most of the genes
were commonly regulated by ERb-selective agonists and E2, there were some genes regulated that were distinct from each
other and E2, suggesting that different ERb-selective agonists might produce distinct biological and clinical effects.
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Estrogens exert their biological effects by interacting with two
known ERs, ERa and ERb [1,2,3,4]. ERs are involved in
development of the reproductive tract and regulation of
reproductive processes [5]. In addition to their role in reproduc-
tion, ERs also have important roles in the breast, bone, brain and
the cardiovascular system [1,2,3,4]. Studies with ERa and ERb
knockout mice demonstrated that ERa is required for the
development of certain tissues in the reproductive tract and
mammary gland [6]. ERb knockout mice (bERKO) show other
defects. There are fewer corpora lutea in the bERKO mice, which
likely accounts for the observation that these mice are subfertile
[7]. In luminal mammary epithelial cells of bERKO mice there
was a widespread increase in the proliferation marker, Ki-67,
suggesting that ERb is important for terminal differentiation of
mammary epithelial cells [8]. Prostate and myelogenous hyper-
plasia have been observed in bERKO mice [9,10]. These mice
also show a loss of anxiety [11] and spatial learning [12], and
developed depression-like behavior [13]. These observations
support a role for ERb in behavior, mood and affective disorders.
Estrogens have been used extensively to treat menopausal
symptoms and osteoporosis in postmenopausal women. The
Women’s Health Initiative (WHI) trial found that the risks
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6271outweighed the benefits of hormone therapy (HT)
[14,15,16,17,18]. It is now thought that some adverse effects of
HT observed in the WHI were due to an older subject population
in the trial [19,20]. However, there remains an intense effort to
discover safer estrogens that selectively regulate ERa or ERb,a s
alternatives to the estrogens currently used in HT regimens that
non-selectively regulate both ERs.
ERb-selective estrogens might be more desirable for HT than
ERa-selective estrogens, because studies indicate that ERa
mediates cell proliferation that contributes to breast and
endometrial cancer whereas ERb generally is thought to
counteract ERa-dependent cell proliferation and tumor formation
[21,22,23]. The first reported ERb-selective estrogen synthesized
and studied was diarylpropionitrile (DPN). DPN has a 70-fold
higher in vitro binding affinity and 170-fold higher potency in
transcription assays with ERb compared to ERa [24]. Other ERb-
selective ligands have been synthesized in both academic and
industrial settings, of which ERB-041 is among the most studied
[7,25]. In addition to synthetic ERb ligands, a plant extract,
MF101 [26] and a flavanone derived from a single plant in
MF101, liquiritigenin [27] are highly ERb-selective compounds.
Studies with ERb-selective compounds indicate that there are at
leastthree classesof ERb-selective agonists. ERB-041 is the prototype
o fal i g a n dt h a ti sa nE R b-selective binder, because it binds to ERb
with a much higher affinity than ERa. In contrast, we showed that
MF101 and liquiritigenin bind similarly to ERa and ERb, but do not
regulate gene transcription in the presence of ERa or stimulate
uterine growth or breast cancer tumor formation in mouse models
[27]. These studies established that some ligands can act as highly
ERb-selective transcriptional activators, even though they bind non-
selectively to both ERa and ERb.At h i r dc l a s so fE R b-selective
agonists is represented by DPN, which is selective by a combination
of preferential binding to ERb and increased transcriptional activity
[24]. An unanswered question is whether different ERb-selective
agonists produce biological effects that are distinct from each other
and non-selective ER agonists used in HT, such as estradiol. To
investigate this issue, we determined if these ERb-selective com-
pounds regulate the same or different genes.
Materials and Methods
Reagents
MF101, liquiritigenin and nyasol were obtained from Bionovo
(Emeryville, CA). ERB-041 was obtained from Wyeth (College-
ville, PA). DPN was obtained from Tocris (Ellisville, MO).
Estradiol was obtained from Sigma-Aldrich Chemical Co. (St.
Louis, MO). All other compounds were obtained as previously
described [27,28,29].
Cell lines and culture
Tetracycline-inducible U2OS-ERa and U2OS-ERb cells were
characterized and maintained as previously described [30]. U2OS,
Caco-2, HeLa, and Ishikawa cells were obtained from the UCSF
cell culture facility and maintained as previously described [28,31].
All experiments were done with cells containing 5% charcoal-
stripped fetal bovine serum.
Fo ¨rster resonance energy transfer (FRET)
U2OS cells (n=500,000) were plated into six-well dish
containing a borosilicate glass coverslip and grown in phenol
red-free DMEM/F12 media supplemented with 5% charcoal-
stripped fetal bovine serum and 2 mM glutamine. The following
day the cells were transfected with 500 ng/well of CFP-ERa-YFP
[32] or CFP-ERb-YFP [26] using Lipofectamine
TM 2000
according to manufacturer’s protocol (Invitrogen, Carlsbad, CA).
After 6 h the medium was replaced with complete medium
containing 10% stripped fetal bovine serum, 2 mM glutamine,
50 U/ml penicillin, 50 mg/ml streptomycin and the cells were
incubated overnight. One day after transfection cells were treated
with the indicated amounts of ligand for 30 minutes before image
collection. Within each independent experiment, an average of
124 cells were collected for each ligand at each concentration and
the amount of FRET averaged by comparing the amounts of
fluorescence in the acceptor bleedthrough corrected FRET
channel to the amount in the Donor channel; the conversion of
these values to the percentage of Energy transferred from CFP to
YFP was done using the calibration methods we have previously
described [33]. For each ligand, the dose response curves were
conducted twice on independent days and presented at the
mean+/2range (Figure 1, open bars). Measurements at 1 mMo f
ligand were repeated on four independent days and presented as
the mean+/2standard deviation (Figure 1, closed bars). In total,
FRET measurements were collected from 35,396 cells expressing
CFP-ERa-YFP or CFP-ERb-YFP and from an additional 4,432
control cells expressing ERa or ERb attached to CFP or YFP
alone.
Microarrays
U2OS-ERa and U2OS-ERb cells were maintained in 5%
charcoal-stripped fetal bovine serum and plated in 6-well plates.
When the cells reached 80% confluent, they were treated with
1 mg/ml doxycycline for 12 h to induce ERs. The cells were then
treated with 10 nM E2, 125 mg/ml MF101, or 1 mM liquiritigenin,
nyasol or DPN for 6 h at 37 C. Total cellular RNA was isolated
with the Aurum RNA isolation kit (Bio-Rad, Hercules, CA) per the
manufacturer’s protocol. RNA was first quantified by standard
spectrophotometry, and then qualitatively evaluated by capillary
electrophoresis employing the Bio-Rad Experion system (Hercules,
CA). Biotin-labeled cRNA samples were prepared with 750 ng of
total RNA template. Following synthesis and purification, the
biotin-labeled samples were evaluated by both 260/280 absor-
bance spectrophotometry and capillary electrophoresis. The final
labeled cRNA samples were hybridized overnight against Human
genome HG U133A-2.0 GeneChip arrays containing more than
22,200 probe sets (Affymetrix, Santa Clara, CA) or 48,000
transcripts HumanWG-6 BeadChip (Illumina, San Diego, CA)
arrays. For the U133A-2.0 GeneChips the array hybridizations,
washing, staining, as well as scanning were performed by the J.D.
Gladstone Genomics Core, (San Francisco, CA), whereas the
Ilumina microarrays were processed at the UCSF Genomics Core.
The drug studies were done with the U133A-2.0 GeneChips and
the four cell type study was done with WG-6 BeadChips. Same
batch of microarrays were used for all treatments and most
treatments were done in triplicate except for NYA treatment in
U2OS-ERa samples in 2 replicates, and E2, MF101, and LIQ
treatment in U2OS-ERb samples in four replicates.
Microarray data analysis
The Affymetrix expression arrays were pre-processed using a
variant of GCRMA [34]. The microarrays were preprocessed with
a procedure similar to GCRMA, except that the background
adjustment step is modified. Instead of using the probe sequence to
predict non-specific binding (as in GCRMA), the non-specific
binding for each probe is estimated from a database composed of
hybridization data on the same platform of microarrays used in a
variety of experiments. The new procedure is therefore dubbed
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separately in dbRMA and avoided borrowing information across
probes sharing similar but not identical sequences. More
specifically, the probe intensity across all the samples in the
database was modeled as a mixture distribution with the first
component as background and estimated using normal approx-
imation. Assessment on calibration data (Affymetrix Latin Square
experiment) showed better accuracy of background parameters
compared to those predicted by sequence. The normalization and
summarization steps in the preprocessing procedures remain the
same as GCRMA. The details of dbRMA procedure will be
presented in a separate manuscript.
The Illumina expression arrays were pre-processed using lumi
package [35]. The differential expression analysis was performed
using limma package [36]. These packages are all available in R/
BioConductor. For drug screen data, probesets were selected for
further analysis if the fold change was greater than 2 and multiple
testing adjusted p-value using Benjamini and Hochberg procedure
(BH-adjusted p-value) was less than 0.05 [37]. For the three cell
line data, fold change threshold 1.5 was used. The heatmaps of log
intensities of genes across different experiments were produced
using Cluster and TreeView software [38]. Cluster software was
used to perform the hierarchical clustering based on Pearson
correlation coefficients (PCC) to find clusters of genes with similar
expression patterns. TreeView was then used to visualize the
clusters and produce the figures.
Functional enrichment analysis of target genes
To elucidate the biological processes of target genes, we
searched enriched GO annotations using GOstat software [39].
For each annotated GO term, GOstat counted the number of
overlapping genes from the input gene list, and compared it with
the one expected from a reference list (GO annotation human
(http://www.ebi.ac.uk/GOA/human_release.html). Fisher’s exact
Figure 1. ERb-selective compounds produce conformational changes with both ERa and ERb at saturating levels. U2OS cells were
transfected with CFP-ERa-YFP (A, C) or CFP-ERb-YFP (B, D) and then treated with 1 mM estradiol, nyasol, liquiritigenin, DPN, ERB-041 (A, B, solid bars)
or with 125 mg/ml MF101 (C, D solid bars). Cells were imaged from 30 to 40 minutes following ligand addition. Percentage of CFP energy transferred
to YFP was not significantly different comparing to its maximum values obtained in dose-response experiments (open bars). The amounts of energy
transferred at the concentration used in the gene profiling studies (1 mM, closed bars) were not statistically different than the amounts at saturation,
with the exception that 1 mM ERB-041, which did not saturate ERa (A). Error bars represent the SD of four independent experiments in which FRET
was collected at 1 mM; the dose response curves were collected in two independent experiments.
doi:10.1371/journal.pone.0006271.g001
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and BH-adjusted p-values were calculated. Results for significant
GO ‘‘biological process’’ categories were reported. To compare
the enriched GO terms cross different experiments, the scores
{log10 of BH-adjusted p-values for each GO term were
combined into one table with GO terms shown in rows and
different experiments shown in columns. Cluster and TreeView
software [38] were then used to produce the GO charts.
Western blot analysis
Caco-2, HeLa and Ishikawa cells were infected with an
adenovirus (100 MOI) that expresses LacZ or ERb [21]. Total
proteins (20 mg) from cells were separated with 4%–12% gradient
Bis-Tris gels (Invitrogen). Proteins were transferred to polyviny-
lidene difluoride (PVDF) membranes (Perkin Elmer) and probed
with anti-ERa (DAKO), or three monoclonal ERb antibodies
(GeneTex) followed by anti-mouse IgG conjugated with horse-
Figure 2. Heatmaps of genes regulated by different compounds in U2OS-ERa or U2OS-ERb cells. Genes regulated by at least one of the
compounds in U2OS-ERa (A) or U2OS-ERb (B) cells are shown in rows. U2OS-ERa or U2OS-ERb cells were treated for 6 h with vehicle, 10 nM E2,
125 mg/ml MF101, ERB-041, nyasol (NYA), liquiritigenin (LIQ) or (diarylpropionitrile) DPN. For each gene (row), entries with no fold change compared
to vehicle control cells are colored yellow, relatively higher expression are colored with reds of increasing intensity, and relatively lower expression are
colored with blues of increasing intensity.
doi:10.1371/journal.pone.0006271.g002
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ECL detection system (GE HealthCare) was used for protein
detection.
RNA extraction and quantitative real-time PCR
Caco-2, HeLa and Ishikawa cells were infected with an
adenovirus (100 MOI) that expresses ERb [21]. After 20 h, the
cells were treated for 6 h with MF101 or LIQ. Total RNA was
extracted with Aurum total RNA mini kit and cDNA synthesis was
performed with the iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA). Real-time PCR analysis was performed in duplicates using
iQ SYBR Green Mix with an iCycler thermal cycler (Bio-Rad,
Hercules, CA). U2OS-ERa and U2OS-ERb were treated with
1 mg/ml doxycycline for 12 h to induce ERs. The cells were then
treated for increasing times with the drugs and real-time PCR was
done using primers for keratin 19 (K19), A kinase (PRKA) anchor
protein 1 (AKAP1), interleukin 17 receptor B (IL17RB). The
sequences of primers used are listed in Table S1.
Results
ERb-selective compounds produce conformational
changes in both ERa and ERb
One goal of this study was to compare the relative ERb-selectivity
of three classes of ERb agonists and to determine if they produce
similar effects on gene expression to each other and E2.T h e
structures of the compounds are shown in Figure S1. ERB-041 is an
ERb-selective binder because it binds 200-fold greater to ERb than
ERa [40]. MF101, liquiritigenin and nyasol are ERb-selective
activators, because they bind similarly to ERa and ERb, but activate
genes only with ERb [26,27]. DPN is a combined ERb-selective
binder and activator because of greater binding to ERb and
transcriptional activity with ERb [24]. For comparison, we chose to
study the effects of these drugs on gene expression at saturating
concentrations of the compounds. FRET was used to determine the
concentration required for saturation of the ligands to ERa and ERb.
The amount of FRET between CFP and YFP attached on opposite
termini of each ER was shown to be a measure of ligand binding in
intact cells [26,32,41]. U2OS cells were transfected with CFP-ERa-
YFP or CFP-ERb-YFP [26,32] and then treated with the
compounds. All of the compounds produced a dose-dependent
enhancement of FRET with both ERa and ERb when added to the
cell culture medium at concentrations ranging from 0.3 nM to 3 mM
(data not shown). The maximal amount of energy transfer at
saturating amounts of ligand is shown for ERa (Figure1A, open bars)
or ERb (Figure 1B, open bars) and is compared to the amounts of
energy transfer detected at the 1 mM concentration (closed bars). All
compounds produced equivalent amounts of energy transfer, above
the no ligand controls, with both ERa and ERb when provided at
saturating levels. Note that the large error bars for ERB-041 at ERa
(Figure 1A, open bars) reflects the variations in the extrapolation of
the dose-response because maximal energy transfer was not achieved
at 3 mM ERB-041 (the highest concentration used).Thus at 1 mM, all
compounds except ERB-041 were able to saturate both ERa and
ERb. Similarly 125 mg/ml of the crude MF101 extract was sufficient
to activate both ERa (Figure 1C) and ERb (Figure 1D). We
previously showed that 1 mM liquiritigenin (LIQ) and 125 mg/ml
MF101 was the concentration that maximally activated reporter
genes [26,27]. Furthermore, 1 mM of nyasol (NYA), ERB-041 and
DPN produced a maximal activation of ERE-tkLuc with ERb in
transfection assays (Figure S2). Based on the transfection and FRET
studies, 1 mM of each compound and 125 mg/mlo fM F 1 0 1e x t r a c t
was used for the subsequent studies to establish the ER subtype-
selectivity of each compound.
MF101, liquiritigenin and ERB-041 are the most ERb-
selective compounds
To investigate the ERb-selectivity of synthetic and natural
compounds, we used the previously characterized human U2OS
cells that are stably transfected with a doxycycline-inducible
expression vector for ERa or ERb [30]. After the cells were
treated with doxycycline to induce ERs, they were treated with E2
and the plant-derived ERb-agonists, MF101, NYA and LIQ, and
the synthetic ERb-agonists, DPN [24] and ERB-041 [40]. We
previously showed that MF101 is a selective ERb agonist despite
being a complex, crude plant extract [26]. LIQ was isolated from
Glycyrrhizae uralensis Fisch and is ERb-selective [27]. NYA is a
diphenylpentane norlignan that was purified from the plant
Anemarrhena asphodeloides in MF101 and has ERb-selectivity using
transfection assays (data not shown). For each compound we
defined a regulated gene to be activated by 2.0-fold or greater or
repressed by 50% or greater and statistically different from the
untreated control cells (BH-adjusted p-value,0.05). The regulated
genes and magnitude of regulation in U2OS-ERa and U2OS-
ERb cells by each drug are found in Table S2. The heatmaps
show the genes that are significantly regulated by the drugs
compared to the control cells. The compounds produced a distinct
pattern of regulated genes in the U2OS-ERa (Figure 2A) cells
compared to U2OS-ERb cells (Figure 2B). The non-ER selective
agonist E2, which was used as a positive control, regulated 489
specific genes in the U2OS-ERa cells relative to the control cells
(Table 1). In the U2OS-ERa cells, there were a total of 238 genes
regulated by DPN and 152 genes regulated by nyasol. The Gene
Ontology (GO) analysis showed that the major classes of genes
commonly regulated in U2OS-ERa cells by E2, nyasol and DPN
were involved in anatomical structure development, multicellular
organismal process and developmental process (Figure S3). ERB-
041 regulated 2 genes in the ERa cells, whereas LIQ and MF101
weakly regulated (between 2–3 fold) 3 and 16 genes in the ERa
cells, respectively. These results demonstrate that relative to E2,
only DPN and NYA showed ERa activity. In contrast, all the
drugs regulated about 400 genes in the U2OS-ERb cells (Table 1).
The heatmap shows that overall the genes regulated by the ERb
agonists were similar to each other and to E2 (Figure 2B). By
comparing the results in the U2OS-ERa and U2OS-ERb cells the
most ERb-selective agonists at saturating levels were ERB-041,
LIQ and MF101 followed by NYA, and then DPN.
Table 1. Summary of genes regulated for each compound in
U2OS-ERa or U2OS-ERb cells.
ERa ERb ERa and ERb
ERB-041 2 379 0
LIQ 3 430 0
MF101 13 382 3
NYA 98 375 54
DPN 143 337 95
E2 489 200 236
Total genes regulated by the compounds, specifically in U2OS-ERa or U2OS-ERb
cells or in both cell types. Numbers are the probe set counts. The cells were
treated for 6 h with 10 nM E2,1 2 5mg/ml MF101 or 1 mM of the other
compounds. Microarrays were performed with U133A-2.0 GeneChips. Genes
with fold change more than 2 and with BH-adjusted p-value,=0.05 were
considered.
doi:10.1371/journal.pone.0006271.t001
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regulated by ERa and ERb were related to the 6 hour treatment
time, we performed time-courses on three regulated genes
(Figure 3). In the U2OS-ERa cells, E2 and DPN maximally
activated AKAP1 (Figure 3A), IL-17 (Figure 3C), and K19
(Figure 3E) at 6 hour. No regulation was observed with other
drugs at all time points. In contrast, all the drugs activated AKAP1
(Figure 3B), IL-17 (Figure 3D), and K19 (Figure 3F) in the U2OS-
ERb cells. The maximal activation of AKAP1 and IL-17 occurred
at 6 hours, whereas K19 was maximally activated by the drugs at
12 h. All of drugs produced the maximal activation of these three
genes at the same time-point in both U2OS-ERa and U2OS-ERb
cells. These findings indicate that the differences in regulation by
drugs in the microarrays were not due to the selection of the
6 hour time-point.
ERb-selective compounds regulate some different genes
in U2OS-ERb cells
Further analysis of the microarray data was done to determine if
the three classes of ERb-selective agonists regulate different genes in
the U2OS-ERb cells. Overall most of genes were commonly
regulated with the ERb-selective compounds (Table 2). The list of
the regulated genes by each compound is found in Table S2.
However, some genes were uniquely regulated by the ERb-selective
Figure 3. Time-course of gene regulation by E2 and ERb-agonists in U2OS cells. U2OS-ERa or U2OS-ERb cells grown in stripped fetal bovine
serum were untreated or treated with doxycycline for 18 hours to induce ERs. The cells were then treated with E2 (10 nM), LIQ (1 mM), NYA(1 mM),
DPN (1 mM), ERB-041(1 mM), and MF101 (125 mg/ml). Following treatment, mRNA levels for AKAP1, IL-17, and K19 were measured at 1, 3, 6 and
12 hours by real-time PCR in U2OS-ERa (A, C, and E, respectively) and U2OS ERb (B, D, and F, respectively) cells. Each data point is the average of
triplicate determinations. Error bars represent the mean6S.E.M.
doi:10.1371/journal.pone.0006271.g003
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genes in common with each other compared to E2 in the U2OS-
ERb cells. The greatest difference in commonly regulated genes
occurred with MF101 and E2, whereas LIQ and DPN showed no
difference in the gene expression profiles. Some genes regulated by
E2 in the ERb cells were also different from those regulated by the
ERb-selective compounds. We performed GO analysis to deter-
mine what classes of genes were regulated similarly and differently
by the ERb agonists. Most of the classes of genes were regulated
similarly, such as developmental process, multicellular organismal
development, system development, organ development, biological
regulation, and negative regulation of cellular process (Figure S4).
However, some classes of genes were differentially regulated by the
ERb-selective drugs and E2 (Figure 4). For example, E2 uniquely
regulated RNA metabolic process genes, whereas NYA regulated
embryonic development genes, MF101 regulated gland develop-
ment genes, LIQ regulated extracellular structure organization
genes and biogenesis, and DPN regulated the regulation of
phosphorylation genes (Figure 4). The magnitude of regulation by
the drugs of several differentially regulated genes is shown in
Figure 5. For comparison, the COL gene was regulated similarly by
all the drugs (Figure 5A). The highest activation of the GPER gene
was observed with MF101 and NYA (Figure 5B), and E2, LIQ,
DPN and ERB-041 for the SOX9 gene (Figure 5C). The ID1 was
repressed the most with E2, MF101, NYA and ERB-041
(Figure 5D). These results demonstrate that while most of the genes
are commonly regulated there are some differences in class of genes
regulated and the magnitude of regulation by the different drugs,
which might be important in producing biological effects.
Cell type-specific regulation of genes with ERb-selective
ligands
To examine whether the ERb-selective ligands regulate genes in
a cell-specific manner, Caco-2, HeLa and Ishikawa cells were
infected with an adenovirus that expresses ERb. These three cell
lines did not express ERa or ERb (Figure 6). The expression of
ERb after the cells were infected with Ad-ERb was similar in the
three cell lines. For microarray analysis, we chose to focus on
MF101 and LIQ, because this allowed us to evaluate if the effects
of a crude extract were similar to a single active compound. The
cells were treated for 6 h with MF101 or LIQ and the gene
expression profiles were determined. Surprisingly, there was very
little overlap in the regulated genes in the three cell lines (Table 3).
Only 3 genes were commonly regulated by MF101 and no genes
were commonly regulated by LIQ in the three cell types. Because
only a few genes were commonly regulated by MF101 and LIQ in
three cell lines, we compared the number of genes commonly
regulated by these drugs in two cell lines (Table 4). The most
overlap with MF101 treatment occurred in the Caco-2 and HeLa
cells with 17 genes commonly regulated. The list of the regulated
genes by MF101 or LIQ in three cell lines is found in Table S3.
The GO analysis showed that not only do MF101 (Figure 7) and
LIQ (Figure S5) regulate different genes, but also that the
regulated genes are involved with different biological processes.
These data demonstrate that there is a remarkable cell-type
specificity of genes regulated by two of the ERb-selective agonists.
We used real-time PCR to examine the regulation by MF101 or
LIQ in the three cell lines infected with Ad-ERb. MF101 or LIQ
increased mRNA levels for ADAMTS-like 5 (ADAMTSL5),
protein tyrosine phosphatase, receptor type, E (PTPRE), retinoic
acid receptor, alpha (RARA), and transglutaminase 2 (TGM2)
genes in HeLa cells (Figure 8A), hydroxysteroid (11-beta)
dehydrogenase 2 (HSD), ectodysplasin-A receptor (EDAR),
chromosome 3 open reading frame 59 (C3orf59) and OTU
domain, ubiquitin aldehyde binding 2 (OTUB2) in Ishikawa cells
(Figure 8B), cytochrome P450, family 1, subfamily A, polypeptide
1, (CYP1A1), cytochrome P450, family 1, subfamily B, polypep-
tide 1 (CYP1B1), baculoviral IAP repeat-containing 3 (BIRC3)
and fibroblast growth factor binding protein 1 (FGFBP1) in Caco-
2 cells (Figure 8C). These results confirm the regulation observed
in the microarrays.
Discussion
The biological effects of estrogens are mediated by ERa and
ERb. All the current estrogens approved for hormone therapy
non-selectively bind to and regulate both ERs. ERa has an
important role in preventing osteoporosis, because males with a
defective ERa develop severe osteoporosis and the increased bone
turnover is not reversed by high-dose estrogen treatment [42].
However, the activation of ERa by estrogens also causes the
proliferation of cells, which increases the risk of breast and
endometrial cancer [18]. The pro-proliferative properties of non-
ER selective estrogens has prevented their use in non-hysterecto-
mized women, and caused an intense effort to discover more
selective estrogens. Drugs that selectively activate ERb are a
particularly attractive alternative for HT, because ERb acts as a
tumor suppressor that inhibits the growth of breast cancer cells
[21,22,23]. The lack of proliferative effects of ERb were also
demonstrated by the observations ERB-041 did not exhibit any
proliferative effects on the mammary glands and uterus of rats
[40], and MF101 and LIQ did not stimulate uterine growth or
breast cancer tumor formation in a mouse xenograft model
[26,27]. Whereas these results indicate that ERb-selective agonists
will not elicit the same proliferative effects as the non-selective
estrogens, it is unclear if they will be beneficial for treating
menopausal symptoms or osteoporosis.
Some ERb-selective compounds did not show any benefits on
hot flashes in rat models indicating that ERb-selective agonists
might not be effective for this classical indication for HT [43]. In
contrast, DPN reduced hot flashes as measured by a reversal of the
elevation in of basal tail skin temperature that occurs after
ovariectomy [44]. The ERb-selective agonist MF101 showed a
statistically significant reduction in hot flashes in a phase 2
randomized placebo controlled study [45]. One possible explana-
tion for these findings is that different classes of ERb-selective
agonists might regulate distinct genes and thereby produce
different biological effects. To examine this possibility, we
compared the ERb-selectivity of synthetic and plant-derived
ERb-selective agonists in U20S cells that express ERa or ERb
using microarrays to study their selectivity over a broad range of
Table 2. Comparison of differentially expressed genes
between compound pairs in U2OS-ERb cells.
E2 ERB-041 NYA MF101 LIQ DPN
E2 0 32 42 168 90 31
ERB-041 32 0 29 52 39 18
NYA 42 29 0 20 13 4
MF101 168 52 20 0 33 32
LIQ 90 39 13 33 0 0
DPN 31 18 4 32 0 0
Numbers are the probe set counts. Genes with fold change more than 1.5 and
with BH-adjusted p-value,=0.05 were considered.
doi:10.1371/journal.pone.0006271.t002
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the most ERb-selective, followed by NYA, and DPN.
The precise mechanism for the ERb-selectivity of the
compounds is unclear. ERB-041 is considered to be an ERb-
selective agonist because it binds to ERb with about a 200-fold
higher affinity compared to ERa [40]. DPN has a 70-fold higher
affinity to ERb, whereas LIQ bound to ERb with a 20-fold higher
affinity [27]. MF101 and NYA bound to ERa and ERb with a
similar affinity [26]. All of these binding studies used in vitro
competition binding assays. To explore the relative binding of the
compounds in living cells, we performed FRET studies in U2OS
cells. Our FRET studies showing that ERB-041 was the only
compound that did not produce any conformational change in
ERa at 1 mM demonstrated that ERB-041 is a selective ERb
binder. In contrast, conformational changes in ERa and ERb
were induced at similar concentrations with MF101, LIQ, NYA
and DPN, demonstrating that these compounds can bind to both
ERa and ERb. However, the gene expression data showed that
Figure 4. Analysis of biological processes differentially enriched among ERb regulated genes between E2 and other compounds.
Gene ontology (GO) terms showing significantly enriched in genes regulated by E2 or other compounds in U2OS-ERb cells. A threshold 0.001 was
used for selecting GO terms using BH-adjusted p-values. {log10 p-value ðÞ was used as an enrichment score. Darker shading denotes more
significantly enriched GO terms, whereas the lightest gray implies the corresponding GO term is not significantly enriched. Only the GO terms
significantly enriched in at least three conditions are shown.
doi:10.1371/journal.pone.0006271.g004
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compounds regulated genes selectively with ERb at this concen-
tration. These results indicate that the conformation of ERa
induced by MF101 and LIQ is essentially inactive, whereas the
conformation induced by NYA and DPN was weakly active. It is
clear that at saturating levels the ERb-selectivity of these
compounds is not related to differential binding to ERb, but
results from events that occur after ligand binding. We previously
showed that MF101 and LIQ did not recruit coactivators to ERa
[26,27], suggesting that compound-bound ERa was in a
conformation that was incapable of binding coactivators. Our
FRET data shows that the conformations produced by all ERb-
selective agonists were similar despite that they showed different
patterns of gene regulation. The FRET study measures the
position of YFP relative to CFP, which appeared to be very similar
when ERb is bound with the different compounds. It is likely that
FRET is not sensitive enough to detect subtle changes in
conformation that led to the differences in gene expression profiles
with the compounds.
One of the most interesting findings of our study is that some
genes regulated by the ERb-selective compounds were not
regulated by E2 in the U2OS-ERb cells. The number of genes
differentially regulated by the ERb agonists compared to E2, range
from 31 with DPN to 168 with MF101. These results demonstrate
that the ERb-selective compounds do not entirely mimic the
action of E2 after binding to ERb, suggesting that they might elicit
different biological effects than E2. While there was no difference
in FRET with E2 and the ERb-selective compounds it is likely that
Figure 5. Gene expression profiles in ERb cells for four regulated genes. In each plot, the y-axis is the log2 of expression intensity and the x-
axis shows the drug index for the control, E2, MF101, NYA, LIQ, DPN, and ERB-041. The collagen, type XVIII, alpha 1 (COL) gene shows a large change
compared to control and no expression change across different drugs with BH-adjusted p-value equal to 1. The other three genes show different
pattern of gene expression profiles across the drugs with BH-adjusted p-values equal to 4e-09 for G protein-coupled estrogen receptor 1 (GPER), 3e-
06 for inhibitor of DNA binding 1, dominant negative helix-loop-helix protein (ID1), and 1e-05 for SRY (sex determining region Y)-box 9 (SOX9). The p-
values here are derived from the F-test comparing the log-intensities across different drugs.
doi:10.1371/journal.pone.0006271.g005
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lead to a differential recruitment of coregulatory proteins and
ultimately different genes regulated. This issue is difficult to
address experimentally because the regulatory elements in the
genes that are differentially regulated by E2 and ERb-selective
agonists as observed with the microarrays are not known.
Our study also demonstrated that two ERb-selective com-
pounds regulated different genes in the three cell lines. Although
the cells were exposed to the same amount of Ad-ERb,
concentration of drugs, and time of drug treatment there was
very little overlap in the regulated genes in the these cell lines.
Unexpectedly, only 3 genes were commonly regulated in all cell
types. The reason for the cell-specific regulation is unknown. It has
been proposed that the differential expression of coactivators in
different cell types might be responsible for cell-specific regulation
[46,47]. Our microarrays showed similar expression of SRC-1,
SRC-2 and SRC-3 in the three cell lines (data not shown). These
findings indicate that the differential expression of these three
classes of coactivators is an unlikely explanation for the different
pattern of gene regulation in the cell lines. Genome-wide tiling
arrays demonstrate that ER binding sites are associated with
different transcription factors that are important for gene
activation [48,49,50]. We also showed that the activation of the
NKG2E gene requires multiple transcription factors (32). These
findings suggest that differential expression of transcription factors
in the cells might lead to the differences in gene regulation.
Another explanation is that there are different epigenetic changes
in the regulated genes in each cell type that allow the recruitment
of cell specific transcription factors as shown with FOXA1 [51]. It
is also possible that the drugs are differentially metabolized in the
three cells. If the metabolites are active this might account for
some of the differences in the genes regulated.
Our study shows several important features of ERb-selective
agonists that could have important clinical ramifications. First,
although most of the genes regulated by the three different classes
of ERb-selective agonists were the same, there were some classes
of genes that were differentially regulated and the magnitude of
regulation of some regulated genes differed. These findings suggest
that different ERb-selective drugs might exert distinct clinical
effects and that it can not be assumed that if one drug fails or
succeeds in clinical trials that other ERb-selective drugs will
behave similarly. Second, the ERb-selective agonists regulate
different genes than E2. These findings suggest that ERb-selective
agonists will have a different side-effect profile than currently
hormone therapy regimens. Although the effect of the ERb-
selective compounds on thromboembolic events is unknown, their
benign effect on the uterus and mammary gland in preclinical
models is a potentially differentiating factor from the non-selective
estrogens. Our hypothesis that different classes of ERb-selective
agonists will produce distinct biological effects needs to be tested in
clinical trials with postmenopausal women.
Supporting Information
Figure S1 Structures of the compounds used.
Found at: doi:10.1371/journal.pone.0006271.s001 (0.21 MB TIF)
Figure S2 Transfection Assays. U2OS cells were transfected
with ERE-tKLuc and an expression vector for ERb. The cells
were treated for 18 h with increasing concentrations of NYA,
DPN and ERB-041. Each data point is the average of triplicate
determinations. Error bars represent the mean6S.E.M.
Found at: doi:10.1371/journal.pone.0006271.s002 (0.21 MB TIF)
Figure S3 Analysis of biological processes enriched among
ERbregulated genes between E2 and other compounds. Gene
ontology (GO) terms showing significantly enriched in genes
Figure 6. Immunoblot of ERa and ERb in different cell lines.
U2OS-ERb cells in the absence (lane1) or presence of doxycycline (lane
2) was used as a positive control for ERb. Ishikawa cells in the absence
(lane 3) or presence (lane 4) of adenovirus (Ad)-ERb, HeLa cells in the
absence (lane5) or presence (lane 6) of Ad-ERb, CaCo-2 cells in the
absence (lane7) or presence (lane 8) of Ad-ERb. U2OS-ERa cells in the
presence of doxycycline (lane 9) was used as a positive control for ERa.
ERa and ERb were detected by immunoblotting with an ERa or ERb
antibodies.
doi:10.1371/journal.pone.0006271.g006
Table 3. Summary of genes regulated by MF101 or LIQ in
three cell lines.









Total genes uniquely regulated by the compounds in each cell line, or
specifically regulated in different combinations of cell lines. Numbers are the
probe set counts. HeLa, Caco-2, or Ishikawa cells were infected with an
adenovirus that expresses ERb for 24 h and were then treated with 125 mg/ml
MF101 and 1 mM LIQ for 6 h. Microarrays were performed with WG-6
BeadChips. Genes with fold change more than 1.5 and with BH-adjusted p-
value,=0.05 were considered.
doi:10.1371/journal.pone.0006271.t003
Table 4. Summary of regulated genes between cell pairs.





MF101 Ishi Caco-2 141 116 2
MF101 Ishi Hela 138 413 5
MF101 Caco-2 Hela 101 401 17
LIQ Ishi Caco-2 123 36 1
LIQ Ishi Hela 122 77 2
LIQ Caco-2 Hela 35 77 2
Numbers are the counts of probe sets regulated by MF101 or LIQ in HeLa, Caco-
2 or Ishikawa (Ishi) cells. Genes with fold change more than 1.5 and with BH-
adjusted p-value,=0.05 were considered. Microarrays were performed with
WG-6 BeadChips.
doi:10.1371/journal.pone.0006271.t004
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threshold 0.001 was used for selecting GO terms using BH-
adjusted p-values. (p-value) was used as an enrichment score.
Darker shading denotes more significantly enriched GO terms,
whereas the lightest gray implies the corresponding GO term is
not significantly enriched.
Found at: doi:10.1371/journal.pone.0006271.s003 (0.44 MB TIF)
Figure S4 Analysis of biological processes commonly enriched
among ERb regulated genes between E2 and other compounds.
Gene ontology (GO) terms showing significantly enriched in genes
regulated by E2 or other compounds in U2OS-ERb cells. A
threshold 0.001 was used for selecting GO terms using BH-
adjusted p-values. (p-value) was used as an enrichment score.
Darker shading denotes more significantly enriched GO terms,
Figure 7. GO charts for genes regulated by MF101 in HeLa, Caco-2 or Ishikawa cells. Analysis of biological processes enriched among
genes regulated by MF101 in HeLa, Caco-2 or Ishikawa (Ishi) cells. Gene ontology terms significantly enriched in genes regulated by MF101 in each of
the four cell lines are shown. A threshold 0.001 was used for selecting GO terms using BH-adjusted p-values. {log10 p-value ðÞ was used as an
enrichment score. Darker shading denotes more significantly enriched GO terms, whereas the lightest gray implies the corresponding GO term is not
significantly enriched.
doi:10.1371/journal.pone.0006271.g007
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PLoS ONE | www.plosone.org 11 July 2009 | Volume 4 | Issue 7 | e6271whereas the lightest gray implies the corresponding GO term is
not significantly enriched. GO terms significantly enriched in at
least three conditions are shown.
Found at: doi:10.1371/journal.pone.0006271.s004 (0.55 MB TIF)
Figure S5 GO charts for genes regulated by LIQ in HeLa,
Caco-2 or Ishikawa cells. Analysis of biological processes
enriched among genes regulated by LIQ in HeLa, Caco-2 or
Ishi cells. Gene ontology terms significantly enriched in genes
regulated by LIQ in each of the fours cell lines are shown. A
threshold 0.001 was used for selecting GO terms using BH-
adjusted p-values. (p-value) was used as an enrichment score.
Darker shading denotes more significantly enriched GO terms,
whereas the lightest gray implies the corresponding GO term is
not significantly enriched.
Found at: doi:10.1371/journal.pone.0006271.s005 (0.27 MB TIF)
Table S1 PCR Primer sequences used for real-time PCR.
Found at: doi:10.1371/journal.pone.0006271.s006 (0.02 MB
XLS)
Table S2 Genes regulated for each compound in U2OS-ERa,
U2OS-ERb cells or both U2OS-ERa and U2OS-ERb cells.
Found at: doi:10.1371/journal.pone.0006271.s007 (0.29 MB
XLS)
Table S3 Genes regulated by MF101 and liquiritigenin in HeLa,
Caco-2 or Ishikawa cells infected with an adenovirus that
expresses ERb.
Found at: doi:10.1371/journal.pone.0006271.s008 (0.08 MB
XLS)
Figure 8. MF101 and LIQ regulation of selected genes in HeLa, Caco-2 or Ishikawa cells. HeLa (A), Ishikawa (Ishi, B) or Caco-2 (C) cells were
infected with an adenovirus that expresses ERb for 24 h. The cells were then treated with 1 mM LIQ or 125 mg/ml MF101 for 6 h. Real-time PCR was
done to measure mRNA levels of ADAMTS-like 5 (ADAMTSL5), protein tyrosine phosphatase, receptor type, E (PTPRE), retinoic acid receptor, alpha
(RARA), and transglutaminase 2 (TGM2) genes in HeLa cells (A), hydroxysteroid (11-beta) dehydrogenase 2 (HSD), ectodysplasin-A receptor (EDAR),
chromosome 3 open reading frame 59 (C3orf59) and OTU domain, ubiquitin aldehyde binding 2 (OTUB2) in Ishikawa cells (B), cytochrome P450,
family 1, subfamily A, polypeptide 1, (CYP1A1), cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), baculoviral IAP repeat-containing 3
(BIRC3) and fibroblast growth factor binding protein 1 (FGFBP1) in Caco-2 cells (C). Each data point is the average of triplicate determinations. Error
bars represent the mean6S.E.M.
doi:10.1371/journal.pone.0006271.g008
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